“Dream Team” of Longevity-Focused R&D Start-Ups Adds Proprietary Data Engine
Life Biosciences today announced it is acquiring Lua, the communication and technology platform. This bold step is intended to facilitate the creation of a proprietary artificial intelligence platform, designed to accelerate Life Biosciences’ research for novel therapies, technologies and drugs to combat age-related decline. Life Biosciences is the first and largest biotech company focused on addressing health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions.
Lua is a web- and mobile-access technology platform focused on improving patient outcomes by facilitating communication between providers and patients. Within Life Biosciences, Lua’s technology will be developed into a platform that is expected to allow faster, comprehensive analysis of study data and the integration of information from scientific studies being conducted by each of the ‘Daughter companies’ within Life Biosciences’ Dream Team business model.
This capability will support all of Life Biosciences’ research to help humans and animals live longer, healthier lives, by ensuring better and faster development of drugs and other treatments. Lua’s direct-to-patient communication model is already at work with demanding healthcare providers, such as Aces ABA, Hospice Partners of America, and The Ensign Group.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“Our Daughter companies are led by the world’s most eminent researchers on age-related decline and longevity,” said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. “Their work will extend into human trials, and for that reason we are thrilled to acquire the powerful Lua platform, which will be available to each of our companies as a proven system for communicating in a HIPAA-compliant environment enabling rich interactivity with a user-friendly interface.”
Date: October 8, 2018
Source: MarketScreener